KRAS and hepatocellular carcinoma: In clinical studies, approximately 3% (1/30 cases) of HCC patients possessed constitutively active mutation of KRAS in which codon 12 of KRAS is mutated from glycine to valine and constitutive activation of Ras/ERK signaling is observed in all cases of over 80 clinical samples.89, 90